The ASI has a new paper out today by Mark Lutter: Instrumental Variables: How the UK can become a world leader in medical innovation.

Lutter argues that the UK must reduce the restrictions on developing new drugs and medical treatments by building a culture and regulatory structure designed around "permissionless innovation"—innovate first, regulate later. People do not just suffer and die from faulty drugs, but also from good drugs being permitted too late. He suggests "reciprocity"—allowing devices and procedures in the UK if they are already permitted in some other highly developed country with similar regulatory standards—as a first step.